AbbVie Inc. is a global, research-based biopharmaceutical company that discovers, develops, and commercializes advanced therapies. Spun off from Abbott Laboratories in 2013, the company focuses on key therapeutic areas including immunology, oncology, neuroscience, and aesthetics. It is known for its biologic drugs such as Humira, Skyrizi, and Rinvoq, as well as its Botox franchise.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
61,160,000
56,334,000
54,318,000
58,054,000
Cost of Sales
18,204,000
16,904,000
20,415,000
17,414,000
Gross Profit
42,956,000
39,430,000
33,903,000
40,640,000
Selling, General & Administrative Expenses
14,010,000
14,752,000
12,872,000
15,260,000
Research & Development Expenses
9,096,000
12,791,000
7,675,000
6,510,000
Other Operating Expenses
4,775,000
2,750,000
599,000
753,000
Operating Profit
15,075,000
9,137,000
12,757,000
18,117,000
Interest Expense
(2,627,000)
(2,160,000)
(1,684,000)
(2,044,000)
Non-Operating Income
(5,851,000)
(3,261,000)
(4,823,000)
(2,596,000)
Total Non-Operating Income
(8,478,000)
(5,421,000)
(6,507,000)
(4,640,000)
Income Before Provision for Income Taxes
6,597,000
3,716,000
6,250,000
13,477,000
Provision for Income Taxes
2,364,000
(570,000)
1,377,000
1,632,000
Consolidated Net Income
4,233,000
4,286,000
4,873,000
11,845,000
Net Income Attributable to Minority Interests and Other
7,000
8,000
10,000
9,000
Net Income Attributable to Common Shareholders
4,226,000
4,278,000
4,863,000
11,836,000
Basic EPS
2.37
2.40
2.73
6.65
Diluted EPS
2.36
2.39
2.72
6.63
Basic Weighted Average Shares Outstanding
1,769,000
1,769,000
1,768,000
1,771,000
Diluted Weighted Average Shares Outstanding
1,773,000
1,773,000
1,773,000
1,778,000
Shares Outstanding
1,768,000
1,765,257
1,765,941
1,769,181
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
5,229,000
5,524,000
12,814,000
9,201,000
Short-Term Investments
28,000
31,000
2,000
28,000
Total Cash and Cash Equivalents
5,257,000
5,555,000
12,816,000
9,229,000
Accounts Receivable
12,589,000
10,919,000
11,155,000
11,254,000
Total Trade Receivables
12,589,000
10,919,000
11,155,000
11,254,000
Inventories
4,951,000
4,181,000
4,099,000
3,579,000
Other Current Assets
6,265,000
4,927,000
4,932,000
4,401,000
Total Current Assets
29,062,000
25,582,000
33,002,000
28,463,000
Net Property, Plant & Equipment
5,628,000
5,134,000
4,989,000
4,935,000
Net Intangible Assets
52,641,000
60,068,000
55,610,000
67,439,000
Goodwill
35,640,000
34,956,000
32,293,000
32,156,000
Long-Term Investments
268,000
279,000
304,000
241,000
Other Long-Term Assets
10,721,000
9,142,000
8,513,000
5,571,000
Total Assets
133,960,000
135,161,000
134,711,000
138,805,000
Accounts Payable
34,734,000
31,945,000
30,650,000
25,402,000
Short-Term Debt
2,499,000
—
—
1,000
Current Portion of Long-Term Debt
6,056,000
6,804,000
7,191,000
4,135,000
Total Current Liabilities
43,289,000
38,749,000
37,841,000
29,538,000
Long-Term Debt
58,941,000
60,340,000
52,194,000
59,135,000
Other Long-Term Liabilities
34,958,000
32,708,000
34,279,000
32,845,000
Total Long-Term Liabilities
93,899,000
93,048,000
86,473,000
91,980,000
Total Liabilities
137,188,000
131,797,000
124,314,000
121,518,000
Common Stock
18,000
18,000
18,000
18,000
Treasury Stock
(9,146,000)
(8,201,000)
(6,533,000)
(4,594,000)
Additional Paid-in Capital
22,495,000
21,333,000
20,180,000
19,245,000
Accumulated Other Comprehensive Income
(1,144,000)
(1,925,000)
(2,305,000)
(2,199,000)
Retained Earnings
(15,493,000)
(7,900,000)
(1,000,000)
4,784,000
Total Common Shareholders' Equity
(3,270,000)
3,325,000
10,360,000
17,254,000
Minority Interests and Other
42,000
39,000
37,000
33,000
Total Shareholders' Equity
(3,228,000)
3,364,000
10,397,000
17,287,000
Total Liabilities and Shareholders' Equity
133,960,000
135,161,000
134,711,000
138,805,000
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
4,233,000
4,286,000
4,873,000
11,845,000
Depreciation & Amortization
8,139,000
8,386,000
8,698,000
8,467,000
Share-Based Compensation Expense
955,000
911,000
747,000
671,000
Other Adjustments
8,065,000
8,005,000
5,708,000
4,054,000
Changes in Trade Receivables
(1,490,000)
207,000
66,000
(1,455,000)
Changes in Inventories
(234,000)
(319,000)
(417,000)
(686,000)
Changes in Income Taxes Payable
(762,000)
(3,208,000)
(488,000)
542,000
Changes in Other Operating Activities
124,000
538,000
3,652,000
1,505,000
Cash from Operating Activities
19,030,000
18,806,000
22,839,000
24,943,000
Capital Expenditure
(1,214,000)
(974,000)
(777,000)
(695,000)
Purchases of Investments
(35,000)
(73,000)
(77,000)
(1,438,000)
Proceeds from Sale of Investments
76,000
555,000
55,000
1,530,000
Payments for Business Acquisitions
(5,441,000)
(20,517,000)
(1,223,000)
(794,000)
Other Investing Activities
(29,000)
189,000
13,000
774,000
Cash from Investing Activities
(6,643,000)
(20,820,000)
(2,009,000)
(623,000)
Issuance of Short-Term Debt
4,798,000
5,008,000
—
—
Repayments of Short-Term Debt
(2,798,000)
(5,008,000)
—
—
Net Issuance / (Repayments) of Short-Term Debt
2,000,000
0
—
—
Issuance of Long-Term Debt
3,994,000
16,963,000
—
2,000,000
Repayments of Long-Term Debt
(6,797,000)
(9,613,000)
(4,149,000)
(14,433,000)
Net Issuance / (Repayments) of Long-Term Debt
(2,803,000)
7,350,000
(4,149,000)
(12,433,000)
Issuance of Common Shares
172,000
214,000
180,000
262,000
Repurchases of Common Shares
(980,000)
(1,708,000)
(1,972,000)
(1,487,000)
Net Issuance / (Repurchases) of Common Shares
(808,000)
(1,494,000)
(1,792,000)
(1,225,000)
Common Share Dividends Paid
(11,657,000)
(11,025,000)
(10,539,000)
(10,043,000)
Other Financing Activities
544,000
(42,000)
(742,000)
(1,102,000)
Cash from Financing Activities
(12,724,000)
(5,211,000)
(17,222,000)
(24,803,000)
Effect of Exchange Rate Changes on Cash and Cash Equivalents
42,000
(65,000)
5,000
(62,000)
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash